Leukocyte telomere shortening in Huntington's disease.
Adult
Age Factors
Aged
Analysis of Variance
Case-Control Studies
Disease Progression
Female
Humans
Huntingtin Protein
/ genetics
Huntington Disease
/ pathology
Leukocytes
/ physiology
Male
Middle Aged
RNA, Messenger
/ metabolism
Regression Analysis
Telomere
/ genetics
Telomere Shortening
/ physiology
Trinucleotide Repeat Expansion
/ genetics
Young Adult
Biomarker
Huntington's disease development
Leukocyte telomere length
Neurodegenerative disease
Journal
Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403
Informations de publication
Date de publication:
15 01 2019
15 01 2019
Historique:
received:
23
07
2018
revised:
26
10
2018
accepted:
26
10
2018
pubmed:
6
11
2018
medline:
23
7
2019
entrez:
6
11
2018
Statut:
ppublish
Résumé
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by an expanded CAG repeat. Though symptom onset commonly occurs at midlife and inversely correlates with the CAG repeat expansion, age at clinical onset and progression rate are variable. In the present study we investigated the relationship between leukocyte telomere length (LTL) and HD development. LTL was measured by real-time PCR in manifest HD patients (HD, n = 62), pre-manifest HD patients (pre-HD, n = 38), and age-matched controls (n = 76). Significant LTL differences were observed between the three groups (p < .0001), with LTL values in the order: HD < pre-HD < controls. The relationship between LTL and age was different in the three groups. An inverse relationship between mean LTL and CAG repeat number was found in the pre-HD (p = .03). The overall data seem to indicate that after age 30 years, LT begins to shorten markedly in pre-HD patients according to CAG number and increasing age, up to the values observed in HD. This very suggestive picture allowed us to hypothesize that in pre-manifest HD, LTL could be a measure of time to clinical HD onset. The possible use of LTL as a reliable biomarker to track HD development and progression was evaluated and discussed.
Identifiants
pubmed: 30396032
pii: S0022-510X(18)30434-9
doi: 10.1016/j.jns.2018.10.024
pii:
doi:
Substances chimiques
HTT protein, human
0
Huntingtin Protein
0
RNA, Messenger
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
25-29Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.